China approves Shanghai Fosun's unit to run human testing for BioNTech's COVID-19 vaccine - Telenor

Breaking

By PanTech

test banner

Post Top Ad

Responsive Ads Here

Post Top Ad

Responsive Ads Here

November 14, 2020

China approves Shanghai Fosun's unit to run human testing for BioNTech's COVID-19 vaccine


(Reuters) Shanghai Fosun Pharmaceutical Group said on Friday that its unit has received clinical trial approval from China’s National Medical Products Administration for a COVID-19 vaccine candidate developed by German firm BioNTech.


The experimental COVID-19 vaccine, BNT162b2, is more than 90% effective based on initial results from large trials outside China, BioNTech’s partner Pfizer Inc said on Monday.


Shanghai Fosun said in a company filing that its unit will begin a Phase II clinical trial in China for the candidate when the conditions are ready.


Source: Reuters; Reporting by Twinnie Siu and Roxanne Liu. Editing by Jane Merriman

No comments:

Post a Comment

Post Top Ad

Responsive Ads Here